Shukra Pharmaceuticals (BOM:524632) Shares Outstanding (EOP): 437.9 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524632 Shukra Pharmaceuticals Ltd BOM:524632
73 GF Score
Price ₹32.84
GF Value ₹8.65
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Shukra Pharmaceuticals Shares Outstanding (EOP)?

Shukra Pharmaceuticals BOM:524632 -0.58% 73 Shares Outstanding (EOP) is 437.9 Mil as of Mar. 2026. GuruFocus rates BOM:524632 with a GF Score™ of 73/100 and a GF Value™ of ₹8.65 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Shukra Pharmaceuticals's shares outstanding for the quarter that ended in Mar. 2026 was 437.9 Mil.

Shukra Pharmaceuticals's quarterly shares outstanding stayed the same from Dec. 2025 (437.9 Mil) to Mar. 2026 (437.9 Mil).

Shukra Pharmaceuticals's annual shares outstanding stayed the same from Mar. 2025 (437.9 Mil) to Mar. 2026 (437.9 Mil).


Shukra Pharmaceuticals  (BOM:524632) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Shukra Pharmaceuticals Shares Outstanding (EOP) Related Terms


Shukra Pharmaceuticals Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Shukra Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shukra Pharmaceuticals Shares Outstanding (EOP) Chart

Shukra Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 300.89 72.02 437.88 437.88 437.88

Shukra Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 437.88 437.88 437.88 437.88 437.88

BOM:524632 vs ZTS, UTHR: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shukra Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shukra Pharmaceuticals Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shukra Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Shukra Pharmaceuticals's Shares Outstanding (EOP) falls into.


BOM:524632
73GF Score
Shukra Pharmaceuticals Ltd BOM:524632
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shukra Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 437.9 Mil mean?
Shukra Pharmaceuticals (BOM:524632) has a Shares Outstanding (EOP) of 437.9 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Shukra Pharmaceuticals and its competitors.
Is Shukra Pharmaceuticals' Shares Outstanding (EOP) too high?
Shukra Pharmaceuticals' current Shares Outstanding (EOP) is 437.9 Mil. Overall, Shukra Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shukra Pharmaceuticals' Shares Outstanding (EOP) compare to ZTS and UTHR?
Shukra Pharmaceuticals' Shares Outstanding (EOP) of 437.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Shukra Pharmaceuticals and its competitors. Shukra Pharmaceuticals's current Shares Outstanding (EOP) is 437.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shukra Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Shukra Pharmaceuticals (BOM:524632) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹8.65, compared to a current price of ₹32.84 — trading 279.7% above its estimated fair value. The current Shares Outstanding (EOP) is 437.9 Mil. Shukra Pharmaceuticals' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Shukra Pharmaceuticals (BOM:524632), the current Shares Outstanding (EOP) is 437.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shukra Pharmaceuticals (BOM:524632) Overvalued in 2026?

Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued. The current stock price of ₹32.84 is trading 279.7% above its estimated GF Value™ of ₹8.65. GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524632:

  • Shares Outstanding (EOP): 437.9 Mil
  • GF Value™: ₹8.65 vs. price of ₹32.84 (279.7% above fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the BOM:524632 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shukra Pharmaceuticals Business Description

Address Judges Bunglow Road, Bodakdev, 3rd Floor, Dev House, Opposite WIAA Office, Ahmedabad, GJ, IND, 380054
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
73GF Score

Get the complete analysis for BOM:524632

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹32.84
Price
₹8.65
GF Value